Clinical Trial Update: Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating thalidomide for bleeding due to gastrointestinal vascular malformations has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Hemorrhage
• Vascular Malformation

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Gastrointestinal Hemorrhage, Vascular Malformation | Phase 2 | Status: WITHDRAWN